Datapoint: Jakafi Approved for Chronic GVHD

The FDA last week approved Incyte Corp.’s JAK inhibitor Jakafi for the treatment of chronic graft-versus-host disease (GVHD) in patients that have not responded to one or two other lines of systemic therapy. Jakafi, which is already approved for the acute form of the disease, currently holds covered or better status for 70% of all insured lives.

SOURCE: MMIT Analytics, as of 9/23/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 30

Datapoint: Exchanges See 4.6 Million Sign-Ups So Far

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 29

Datapoint: Could Georgia Expand Medicaid?

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 28

Datapoint: Froedtert Health Set to Acquire Wisconsin Insurer

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today